FDA permits first oral tablet for chemotherapy-induced diarrhea in dogs

The U.S. FDA (Food and Drug Administration) has conditionally approved Canalevia-CA1 for treating chemotherapy-induced diarrhea in dogs. This is the very first treatment that has received approval for this condition.

Steven M. Solomon, D.V.M., M.P.H., director of the FDA’s Center for Veterinary Medicine, said that diarrhea is the common side effect among dogs undergoing chemotherapy, which can be more severe and can lead to halting of the treatment.

Most of the time, chemotherapy drugs have probable side effects in humans and dogs, but humans can tolerate some discomfort. However, the main objective of offering cancer treatment to dogs and other pets is to increase survival without sacrificing the quality of life and comfort.

This new medication will offer dog owners and veterinarians required tools for controlling the side effects of chemotherapy for dogs undergoing such treatment.

Canalevia-CA1 can be availed by prescription as expertise of professional veterinary is required for diagnosing the cause of diarrhea properly and monitoring the dogs while receiving chemotherapy.

Canalevia-CA1 is a tablet taken by mouth and can be given for home treatment.

Crofelemer, an active ingredient in Canalevia-CA1, is permitted for treating non-infectious diarrhea in human patients with HIV/AIDS who take antiretroviral therapy.

Conditional approval empowers the drug sponsor to legally use the product in the market for selling after demonstrating that the drug is safe and manufactured with complete consent standards. In addition, there is a rational expectation of the drug’s effectiveness.

The most common side effects around the laboratory and field studies were abnormal feces (soft, mucoid, watery, discolored feces), decreased activity and appetite and vomiting.

Additionally, veterinarians should discuss the possible side effects of the drug with owners before using it. The FDA advises dog owners to report any adverse events or side effects possibly potentially related to the use of any drug, including Canalevia-CA1.

Source Credit - https://www.fda.gov/news-events/press-announcements/fda-conditionally-approves-first-oral-tablet-treat-chemotherapy-induced-diarrhea-dogs